Peptide profile
Davunetide
Also known as NAP, AL-108
ADNP-derived peptide studied in microtubule regulation
Clinical research
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
The randomized phase 2/3 trial did not demonstrate efficacy in progressive supranuclear palsy. Proposed mechanisms should not be presented as established neuroprotection.
View the supporting source- Research area
- Neuroscience
- Biological target or mechanism
- ADNP-derived peptide studied in microtubule regulation
- Evidence context
- Clinical research
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
